Lanluma and Sculptra are made of the same active material and are not the same product. Both are poly-L-lactic acid, or PLLA. It is a biodegradable polymer, injected as tiny particles so the body lays down collagen around them. Sculptra holds a US FDA approval. Lanluma has no US FDA approval and no US clearance.
The reason most people are comparing them is the body. Lanluma is marketed in the UK and Europe under a CE mark. Sinclair has announced a launch positioning it for cellulite and buttock reshaping. Sculptra's US approvals are entirely facial. You may be reading this because you want poly-L-lactic acid in your buttocks or thighs. That is the real question on this page, and the answer is more complicated than a brand choice.
The FDA's position on injecting filler into the body is explicit. The agency recommends against using dermal fillers or any injectable filler for body contouring and enhancement. It names increasing the size of the buttocks specifically. That guidance is not about Lanluma or Sculptra in particular. It covers the whole category, including off-label body use of a facially approved product.
Neither one can be dissolved. Hyaluronidase breaks down hyaluronic acid. It does nothing to poly-L-lactic acid, whichever brand it came in. Over a large area, with a lot of product, that is a bigger commitment than it sounds.
Lanluma has no FDA premarket approval and no FDA clearance. It is not approved and not cleared in the US. It is CE-marked and marketed in the UK and Europe.
Named indications: facial fat loss in people with HIV (3 August 2004), shallow to deep nasolabial fold contour deficiencies and other facial wrinkles suited to a deep dermal cross-hatch technique (2009), and fine lines and wrinkles in the cheek region (2023).
Sinclair has announced a launch positioning Lanluma for cellulite and buttock reshaping. That is the manufacturer's own positioning, and the launch details and market list are not independently confirmed.
Every area named in Sculptra's approvals is on the face. Body use is off-label, which is legal and common, but it means no regulator has reviewed evidence for it.
There is no peer-reviewed trial of Lanluma itself. The general poly-L-lactic acid literature exists, but it is not this product's evidence.
The 2009 nasolabial fold trial randomized 233 people against a collagen comparator, evaluator-blinded, with an extension to month 25. The 2023 cheek trial randomized 149 people at 13 US sites against no treatment: 70.7% responders at month 12 against 25.9%. Both were sponsored by the manufacturer.
Vial formats, the poly-L-lactic acid content per vial and the recommended reconstitution are not confirmed by any primary manufacturer document that is publicly retrievable. Reseller listings should not be treated as specifications.
367.5 mg of freeze-dried powder per vial containing poly-L-lactic acid microparticles with sodium carboxymethylcellulose and mannitol, reconstituted with 5 mL or 8 mL of sterile water. An older labelling format states 150 mg as the polymer content; both figures circulate and they describe different things.
The 2009 trial allowed up to four sessions about three weeks apart with a maximum of 2.5 mL per nasolabial fold; the 2023 trial averaged 3.6 sessions with a maximum of 9 mL per cheek.
Buying or injecting Lanluma in the US means using a product the FDA has not reviewed. The FDA's consumer guidance says not to buy dermal fillers sold directly to the public and warns that such products may be fake, contaminated, or not approved for use in the US.
Poly-L-lactic acid is used off-label on the body. There is some published safety data on that use. Read what it is before you rely on it.
The largest is a real-world safety review of 498 people treated with poly-L-lactic acid in non-facial areas. Nodules were reported in 0.2%, which was one person. The most common adverse event was bruising at 5.0%. Reconstitution in that group was generally 10 mL per vial or more. Roughly half used 10 to 15 mL and roughly half used 15 mL or more. A separate body-contouring series of 20 people reported a nodule in one, or 5%. Both of those author groups include Galderma-affiliated co-authors. Neither is a randomized trial.
Those numbers are reassuring on nodules. They say nothing about whether the result looks good, how long it lasts, or how it compares with anything else. Neither study was a Lanluma study.
Two things follow. First, high dilution matters more on the body than anywhere else. You are covering a large area, and the historical nodule problem with poly-L-lactic acid was worst when it was mixed thin. Second, the FDA's blanket recommendation against injectable filler for body contouring stands over all of it. A clinician can legally treat a body area off-label. That is different from a regulator having looked at the evidence and agreed.
It is tempting to treat "both are PLLA" as the end of the analysis. It is not.
What a poly-L-lactic acid product actually does in tissue depends on particle size, particle shape, how evenly the powder disperses when it is mixed, and what else is in the vial. Those are manufacturing properties, and they differ between products. The published literature on poly-L-lactic acid nodules repeatedly attributes them to microaggregates from incomplete reconstitution - a manufacturing and preparation issue, not a property of the molecule.
For Sculptra those properties are described in FDA documents anyone can read. For Lanluma they are not publicly documented in any primary manufacturer instruction sheet that can be retrieved, and reseller pages are not a substitute. You cannot check a specification that has not been published.
It does not mean the product is dangerous. It means no US regulator has looked at data for it, so the ordinary safety net is absent in three specific ways.
There is no reviewed labelling, so there is no agreed dilution, depth or maximum volume to hold an injector to. There is no adverse event reporting route tied to a US approval, so problems do not accumulate anywhere a future patient can read. And there is no legitimate US supply chain, which is a practical safety issue rather than a paperwork one: in a 2026 hospital series of injectable complications, over half the products involved were uncertified or of unknown origin.
The FDA's own consumer guidance is short on this point. Do not buy dermal fillers sold directly to the public. Products sold that way may be fake, contaminated, or not approved for use in the US.
Everything about this comparison gets bigger on the body.
The volume of product goes up, so the total amount of material that cannot be removed goes up with it. The number of sessions goes up, so the cost of a course does too. And the assessment problem gets worse: poly-L-lactic acid shows almost nothing on the day, so an injector treating buttocks or thighs is making a judgement about how much to place before anyone can see the effect of the last session.
That is the argument for spacing sessions widely and treating conservatively, and it is why the published body protocols use much higher reconstitution volumes than the face.
Go to an emergency department or call 911 for any of these after an injection of either product:
Sudden change or loss of vision in either eye
Sudden severe pain, or pain out of proportion to the procedure
Skin turning white or blanched, then dusky, grey or mottled
Weakness, drooping, slurred speech or any stroke-like symptom
These can mean material has entered an artery. Poly-L-lactic acid cannot be dissolved, so there is no rescue injection to give and the only lever anyone has is how fast you are assessed.
Swelling keeps increasing after the first few days instead of settling
A firm lump appears under the skin, whether at three weeks or at six months
Redness spreads outward from a treated area, or you develop a fever
An area becomes tender or swollen weeks later, particularly after an illness, a vaccination or dental work
A treated area builds up unevenly as the collagen response develops